Analyst Reco. Elutia Inc.

Equities

ELUT

US05479K1060

Delayed Nasdaq Other stock markets 10:35:10 2024-06-10 am EDT			5-day change	1st Jan Change
3.474 ^USD	+1.87%		+3.70%	+60.82%

May. 09	Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantor Fitzgerald Cuts Elutia's Price Target to $6 From $8, Keeps Overweight Rating	Nov. 14	MT
Lake Street Initiates Elutia at Buy Rating With $3 Price Target	23-09-28	MT
Equity Futures Trend Higher as Investors Expect No Rate Hike From Fed	23-09-19	MT
Cantor Fitzgerald Trims Price Target on Aziyo Biologics to $10 From $12, Maintains Overweight Rating	23-05-12	MT
Turist Securities Adjusts Aziyo Biologics Price Target to $10 From $8, Maintains Buy Rating	22-11-16	MT
Piper Sandler Adjusts Price Target on Aziyo Biologics to $10.50 From $9, Maintains Overweight Rating	22-11-15	MT
Cowen Adjusts Aziyo Biologics' Price Target to $13 From $15, Keeps Outperform Rating	22-03-04	MT
Piper Sandler Adjusts Aziyo Biologics' Price Target to $9 From $11, Reiterates Overweight Rating	22-03-04	MT
Piper Sandler Adjusts Aziyo Biologics' Price Target to $11 From $14, Reiterates Overweight Rating	21-11-10	MT
AZIYO BIOLOGICS : Piper Sandler Adjusts Aziyo Biologics PT to $14 From $20, Maintains Overweight Rating	21-06-07	MT
AZIYO BIOLOGICS : Cantor Fitzgerald Starts Aziyo Biologics at Overweight With $20 Price Target	20-11-02	MT
AZIYO BIOLOGICS : Cowen Starts Aziyo Biologics at Outperform With $20 Price Target	20-11-02	MT
AZIYO BIOLOGICS : Truist Securities Starts Aziyo Biologics at Buy With $20 Price Target	20-11-02	MT
AZIYO BIOLOGICS : Piper Sandler Starts Aziyo Biologics at Overweight With $20 Price Target	20-11-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer